» Articles » PMID: 15668888

High-throughput Tissue Microarray Analysis of C-myc Activation in Chronic Liver Diseases and Hepatocellular Carcinoma

Overview
Journal Hum Pathol
Specialty Pathology
Date 2005 Jan 26
PMID 15668888
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Amplification of 8q23-qter is common in human hepatocellular carcinoma (HCC). c-myc, an oncogene located on 8q24, may be important in hepatocarcinogenesis. The present study aimed to evaluate c-myc activation in hepatocarcinogenesis and its clinicopathological significance. High-throughput analysis of c-myc gene amplification and expression using dual-color fluorescence in situ hybridization and immunohistochemistry was performed on tissue microarrays consisting of 458 liver samples comprising HCCs, nontumorous livers and normal livers. HCCs demonstrated frequent c-myc amplification (30% when corrected for chromosome 8 aneusomy). In contrast, the noncancerous livers, which were mostly chronic hepatitis and cirrhosis, exhibited no c-myc amplification. Despite c-myc amplification, the HCCs exhibited less nuclear c-myc expression than the livers with chronic liver diseases and normal livers (P <0.001 and 0.004, respectively). The HCCs also had less cytoplasmic c-myc staining than the livers with chronic liver diseases (P = 0.002). Despite their absence of c-myc amplification, however, the livers with chronic disease had significantly increased expression of both nuclear and cytoplasmic c-myc protein compared with normal livers (P = 0.015 and 0.009, respectively). Clinicopathologically, the reduction in nuclear c-myc was more marked in HCCs with venous permeation and absence of tumor encapsulation (P = 0.013 and 0.021, respectively), whereas HCCs with cytoplasmic c-myc were positively associated with larger tumor size (P = 0.027). There was no significant association between c-myc amplification and protein expression levels in HCC. Our results suggest that overexpression of c-myc in chronic liver diseases may play an important role in the predisposition to hepatocarcinogenesis. Although c-myc was amplified in HCC, there appears to be a tight regulation by independent pathways of c-myc activation in hepatocarcinogenesis.

Citing Articles

GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway.

Tiu Y, Gong L, Zhang Y, Luo J, Yang Y, Tang Y Cancer Gene Ther. 2022; 29(11):1720-1730.

PMID: 35760898 DOI: 10.1038/s41417-022-00490-1.


MiR-138 is a potent regulator of the heterogenous MYC transcript population in cancers.

Desi N, Teh V, Tong Q, Lim C, Tabatabaeian H, Chew X Oncogene. 2021; 41(8):1178-1189.

PMID: 34937878 PMC: 8856960. DOI: 10.1038/s41388-021-02084-x.


Up-regulation of CLIC1 activates MYC signaling and forms a positive feedback regulatory loop with MYC in Hepatocellular carcinoma.

Jiang X, Liu Y, Wang G, Yao Y, Mei C, Wu X Am J Cancer Res. 2020; 10(8):2355-2370.

PMID: 32905514 PMC: 7471371.


Genome-wide promoter DNA methylation profiling of hepatocellular carcinomas arising either spontaneously or due to chronic exposure to Ginkgo biloba extract (GBE) in B6C3F1/N mice.

Kovi R, Bhusari S, Mav D, Shah R, Ton T, Hoenerhoff M Arch Toxicol. 2019; 93(8):2219-2235.

PMID: 31278416 PMC: 6830449. DOI: 10.1007/s00204-019-02505-7.


Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma.

Lai I, Swaminathan S, Baylot V, Mosley A, Dhanasekaran R, Gabay M J Immunother Cancer. 2018; 6(1):125.

PMID: 30458889 PMC: 6247677. DOI: 10.1186/s40425-018-0431-x.